secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001723128-24-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reaffirms FY2023 guidance: revenue $2.37-2.42B, adj. EBITDA $540-550M
----------------------------------------------------------------------------

- Reaffirmed 2023 guidance previously issued on Nov 7, 2023 at an investor conference on Jan 10, 2024.
- Net revenue range $2.37-$2.42 billion; adjusted EBITDA $540-$550 million.
- Adjusted diluted EPS $0.51-$0.58; operating cash flow $250-$280 million.
- Capital expenditures $50-$60 million; weighted average diluted shares ~310 million.
- Guidance includes 100% of AvKARE Adjusted EBITDA and 35% non-controlling interest in EPS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000003/0001723128-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000003/amrx-20240110.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer